Ascletis Submits Two IND Applications to the U.S. FDA for the Treatment of Obesity: ASC36 Once-Monthly Injection, a Peptide Amylin Receptor Agonist, and ASC36_35 FDC Once-Monthly Injection, a Co-Formulation of ASC36 Plus Peptide GLP-1R/GIPR Agonist ASC35

Summary

Ascletis submitted two IND applications to the U.S. FDA for obesity treatments: ASC36, a peptide amylin receptor agonist once-monthly injection, and ASC36_35 FDC, a co-formulation targeting amylin receptor, GLP-1R, and GIPR. ASC36_35 FDC demonstrated approximately 51% greater relative body weight reduction.